BioAtla Inc. (NASDAQ: BCAB)
$1.84
+0.0900 ( +5.14% ) 100.8K
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
Market Data
Open
$1.84
Previous close
$1.75
Volume
100.8K
Market cap
$89.26M
Day range
$1.72 - $1.86
52 week range
$1.14 - $4.02
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Apr 01, 2024 |
8-k | 8K-related | 12 | Mar 26, 2024 |
10-k | Annual reports | 74 | Mar 26, 2024 |
4 | Insider transactions | 1 | Mar 01, 2024 |
4 | Insider transactions | 1 | Mar 01, 2024 |
8-k | 8K-related | 12 | Feb 21, 2024 |
4 | Insider transactions | 1 | Feb 20, 2024 |
4 | Insider transactions | 1 | Feb 20, 2024 |
4 | Insider transactions | 1 | Feb 20, 2024 |
4 | Insider transactions | 1 | Feb 20, 2024 |